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In 2004, three groups working independently [1–3] , almost simultaneously, reported remarkable 
findings: that activating mutations in the epidermal growth factor receptor (EGFR) were 
common in certain lung carcinomas and that these mutations correlated with the response of 
those lung tumors to therapy with gefitinib and erlotinib, both EGFR tyrosine kinase inhibitors 
(TKIs). This was the first time driver mutations in lung cancer that responded to targeted therapy 
had been identified, marking the beginning of a new era of personalized medicine in lung cancer. 
Prior to the discovery of these mutations, patients had been treated with EGFR TKIs but 
predicting who would respond and who would not was only imperfectly correlated with the 
histologic appearance of the tumor and the clinical profile of the patient. 
 
The lung cancer landscape has rapidly shifted in less than a decade since these discoveries. 
Pathology now drives treatment selection with the knowledge that there are histology-specific 
mutations and treatment agents readily available [4] . Departments of pathology have responded 
by refining criteria for the separation of nonsmall cell lung cancer (NSCLC), increasing the size 
and scope of diagnostic molecular laboratories and collaborating with clinical colleagues on an 
unprecedented level. 
The search for new, targetable mutations in lung cancer has resulted in discoveries and 
frustrations and dramatic changes in the pathology practice. In this evolving scenario some 
questions seem relevant: where does cytology fit into this new era? How is the practice of 
cytology poised to ask and answer the necessary questions? How does the cytologist do ‘more 
and more with less and less’? We know that most lung cancer patients present with advanced 
disease and that diagnosis will be made on cytology and small biopsy specimens [5] . According 
to the 2012 National Comprehensive Cancer Network (NCCN) guidelines [6] , the first step in 
the therapy for recurrent or metastatic NSCLC is the establishment of histologic subtype and the 
second step is testing for EGFR mutations and ALK fusions yet nowhere is the word cytology 
even mentioned. In some of these patients, the only diagnostic and analyzable material is the one 
obtained from an FNA biopsy. 
 
In an attempt to guide the cytopathologist and offer strategies to navigate this new territory, this 
issue of Acta Cytologica, devoted to lung cancer, brings together data and techniques from 
international experts in the field of diagnosis, testing, epidemiology, new discoveries, and 
markers, and offers a multidisciplinary approach to these questions. New technologies are also 
highlighted, showing just how much can be done with limited material.  
We begin this special issue by looking at data that supports the use of FNA in the diagnosis and 
classification of both primary and metastatic lung tumors, with the ability of cytology to classify 
the vast majority of NSCLC into adenocarcinoma or squamous carcinoma. This first step is 
crucial in matching the appropriate tumor samples to the appropriate testing or therapeutic 
agents. Adams and Wu [7] demonstrate this high accuracy in a retrospective examination of over 
1,000 cases. If cytomorphology alone is inadequate tor the subclassification of NSCLC, 
immunocytochemical staining takes on more importance. Johnson et al. [8] conclude that the use 
of Dako TTF-1 antibody paired with Leica Napsin A antibody as a double stain yields the best 
result for diagnosing adenocarcinoma. Additionally, using the Leica Napsin A as a single stain 
resulted in the highest positive predictive value of 97% for adenocarcinoma. Once the subtype of 
carcinoma is determined, the NCCN guidelines recommend that all adenocarcinomas, large cell 
carcinomas, and NSCLC not otherwise specified be tested for targetable molecular abnormalities 
in EGFR and ALK. In fact, this has led to the use of a new, nonpathologic term, ‘nonsquamous 
histology’, favored by clinicians to indicate what lung carcinomas should be tested and to guide 
therapy, as bevacizumab and pemetrexed are to be avoided in squamous cell carcinoma patients 
due to inefficacy and toxicity, respectively. This term nicely demonstrates the interplay, usually 
but not always welcome, between pathologists and clinicians in the practical triage and treatment 
of lung cancer. Assigning mutation status in lung cancer is increasingly possible at the 
immunocytochemical level. As Moreira and Hasanovic [9] demonstrate, new mutation-specific 
antibodies can be employed as an alternate or adjunct to standard molecular testing using limited 
cytology material. Antibodies to the EGFR exon 19 deletion mutant and the EGFR L858R 
mutant can be used in material that has undergone decalcification and that may be unsuitable for 
molecular testing. More recently, a sensitive antibody to ALK suitable for the detection of 
EML4-ALK has been made available [10] . How this will play a role in the determination of 
ALK fusion status and the selection of crizotinib as appropriate therapy compared to fluorescent 
in situ hybridization (FISH) has yet to be determined. As more molecular testing is translated 
into mutation-specific antibodies, we can expect expanded application to cytology material. 
FISH is a powerful tool in the field of predictive marker analysis in cancer and is increasingly 
useful in the study of lung cancer. Savic and Bubendorf [11] provide an overview of the current 
role of FISH in respiratory cytology pointing out that it has become the gold standard in the 
identification of AL rearrangements. With the discovery of novel gene fusions involving the 
tyrosine kinases ROS1 and RET as additional driver mutations in NSCLC [12] , FISH 
methodology becomes increasingly essential.  
Turning to the technical aspects of molecular testing, Roy-Chowdhuri et al. [13] demonstrate the 
first semiautomated, computer-guided laser capture microdissection (LCM) of cytology 
specimens using SIVQ and AutoScan as a first step in integrating LCM into clinical cyto-
molecular testing. Arcila [14] outlines a simple protocol for obtaining DNA from archival 
cytology material that is currently in use at the Memorial Sloan-Kettering Cancer Center 
(MSKCC) where hundreds of cytology specimens including cell blocks, fluids, ThinPreps, and 
direct smears have been analyzed for molecular abnormalities. Elnekave and Thornton [15] 
provide an overview of how the interventional radiologist, working as part of a team that 
includes cytotechnologists, can obtain the most adequate specimen possible and they provide an 
overview of the current best practices in this area.  
Looking towards new approaches to the classification and molecular profiling of lung tumors, 
Solomides et al. [16] outline a novel algorithm for specimen classification of poorly 
differentiated NSCLC using microRNA profiling. This technique is readily applicable to 
cytology cell block material. Young et al. [17] summarize the state of circulating tumor cell 
(CTC) detection today with particular emphasis on lung cancer and discuss the future 
applications of CTCs in helping the clinician develop new 
strategies in patient treatment.  
 
For reasons that are still unclear, EGFR mutations are more commonly found in the Asian 
population. Ma et al. [18] bring us a perspective from a high incidence area, Hong Kong, with 
the comparison of EGFR gene mutation testing in surgical and cytology specimens concluding 
that cytology specimens had a lower detection rate of EGFR mutation (40%) as compared to 
surgical specimens (48%) but state that the material inadequacy issues in cytology 
specimens may be overcome by tumor cell enrichment strategies and employment of mutation 
detection techniques with increased analytical sensitivity. This experience is, interestingly, not 
universal [19] and the use of the techniques described by Elnekave and Thornton [15] , Arcila 
[14] , and Roy-Chowduri et al. [13] in this issue may address some of the specimen adequacy 
problems encountered in their practice. 
 
To aid the cytopathologist in case management and specimen triage, Goyal et al. [20] 
demonstrate that Tele-Cyt can serve as a powerful alternative, time-efficient strategy for real-
time FNA interpretation in a busy practice or in one that includes ‘off-site’ centers. 
 
 
Finally, the group from the Mayo Clinic [21] brings the unique perspective that changes in 
cytology clinical practice due to the decrease in Pap test volumes – expected to further decrease 
with the new screening guidelines [22] – has resulted in evolving and expanding roles for many 
cytotechnologists including involvement in DNA ploidy analysis, quantitative 
immuncytochemistry, FISH, CTC recognition, and molecular oncology testing. As shown in the 
article by Elnekave and Thornton [15] , the presence of cytotechnologists is essential to some 
new settings and the expertise of the cytotechnologist may become more crucial in this new 
cancer era.  
 
The opportunities for cytopathologists to influence therapy, direct management, and uncover 
strategies in the complex field of cancer are exciting and limitless. Lung cancer has served as a 
role model in this emerging era. We hope that our readers will find this special edition of Acta 
Cytologica a useful guide in navigating this new territory. 
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